Sign In
Free Newsletter
Merck takes next step in $1.35B Imago buy
The Rahway-based company announced Dec. 12 that it will file with the U.S. Securities and Exchange Commission a cash tender offer statement to purchase all outstanding shares of the target's common stock.
Merck to buy Imago for $1.35B
The target is a California-based biopharmaceutical company that focuses on developing treatments for myeloproliferative neoplasm and other bone marrow diseases.
Merck expands partnership with software company
As part of the arrangement, the Kenilworth-headquartered pharmaceutical company will opt for the Barcelona-based firm's cloud-based platform and products first, when applicable, in exchange for a strategic pricing agreement.
Davis to succeed Frazier as Merck chairman
Current CEO and President Robert Davis will take on the position before the end of the year as Executive Chairman Kenneth Frazier retires from that post.
Two NJ companies rank at top of 100 Best ESG Companies list
Based on a combination of environmental, social and governance ratings and strong fundamental and technical stock performance, global data analytics provider Verisk and pharmaceutical giant Merck secured high scores.
NJ companies make Fortune’s ‘Change the World’ list (updated)
Four dozen firms worldwide were recognized for enacting business strategies that have had a positive impact in the world to address social or environmental issues through profit-making operations. See which Garden State organizations made the cut.
Merck Foundation launches $20M cancer care initiative
“The severity of the need to take action on advancing equity in cancer care cannot be overstated and will not be overlooked,” Foundation CEO Carmen Villar said.
Merck ESG initiatives include $1B sustainability bond to support goals
"ESG underpins our Corporate Strategic Framework and every decision we make,” Merck CEO and President Robert Davis said after the Rahway biopharmaceutical company released its 2021/2022 Environmental, Social and Governance Progress Report.
Merck announces $150M collaboration with Orna Therapeutics
The Cambridge Mass.-based biotech company will also be eligible to receive up to $3.5 billion in development, regulatory and sales milestones, as well as royalties on any approved products created from the deal.
Merck, NJII launch support studio for biomedical startups
Applications are open to join the Merck Digital Sciences Studio accelerator, which was designed to enable technology generation for drug discovery and development.
Longtime exec returns to Merck as CMO for Human Health
Chirfi Guindo originally joined the company in 1990 and spent more than 25 years in finance, sales, commercial and marketing roles in the U.S. and globally.
$65M grant funds joint academic-pharma drug accelerator
Experts – including those from Hackensack Meridian Center for Discovery and Innovation in Nutley, Rutgers University and Merck in Rahway – are joining forces to research and produce treatments for viral threats.
